European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | España |
| Recursos: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/174282 |
| Acesso em linha: | https://hdl.handle.net/2445/174282 |
| Access Level: | acceso abierto |
| Palavra-chave: | Infeccions per Helicobacter pylori Terapèutica Helicobacter pylori infections Therapeutics |
| id |
ES_1a616dc3d89ec57ad2e30c8f12b0eca4 |
|---|---|
| oai_identifier_str |
oai:diposit.ub.edu:2445/174282 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in SpainCaldas, MaríaPérez Aisa, ÁngelesCastro Fernández, ManuelBujanda, LuisLucendo, AlfredoRodrigo, LuisHuguet, José María Pérez Lasala, JorgeMolina Infante, JavierBarrio, JesúsFernández Salazar, LuisLanas, ÁngelPerona, MónicaDomínguez Cajal, ManuelOrtuño, JuanGómez Rodríguez, BlasAlmela, PedroBotargués, Josep MaríaNúñez, ÓscarModolell, InésGómez, JudithRuiz Zorrilla, RafaelCoba, Cristóbal De LaHuerta, AlainIyo, EduardoPozzati, LilianaAntón, RosarioBarenys de Lacha, MercéAngueira, TeresaFernández Bermejo, MiguelCampillo, AnaAlcedo, JavierPajares Villarroya, RamónMego, MarianelaBermejo, FernandoDomínguez Jiménez, JoséTitó, LlúciaFernández, NuriaPabón Carrasco, ManuelCosme, ÁngelMata Romero, PilarAlcaide, NoeliaAriño, InésMaira, Tommaso DiGarre, AnaPuig, IgnasiNyssen, Olga P.Megraud, FrancisO’Morain, ColmGisbert, JavierInfeccions per Helicobacter pyloriTerapèuticaHelicobacter pylori infectionsTherapeuticsThe management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain.MDPI2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/174282Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/antibiotics10010013Antibiotics, 2020, vol. 10, num. 1https://doi.org/10.3390/antibiotics10010013cc by (c) Caldas et al., 2020http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1742822026-05-27T06:46:51Z |
| dc.title.none.fl_str_mv |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| title |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| spellingShingle |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain Caldas, María Infeccions per Helicobacter pylori Terapèutica Helicobacter pylori infections Therapeutics |
| title_short |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| title_full |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| title_fullStr |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| title_full_unstemmed |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| title_sort |
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
| dc.creator.none.fl_str_mv |
Caldas, María Pérez Aisa, Ángeles Castro Fernández, Manuel Bujanda, Luis Lucendo, Alfredo Rodrigo, Luis Huguet, José María Pérez Lasala, Jorge Molina Infante, Javier Barrio, Jesús Fernández Salazar, Luis Lanas, Ángel Perona, Mónica Domínguez Cajal, Manuel Ortuño, Juan Gómez Rodríguez, Blas Almela, Pedro Botargués, Josep María Núñez, Óscar Modolell, Inés Gómez, Judith Ruiz Zorrilla, Rafael Coba, Cristóbal De La Huerta, Alain Iyo, Eduardo Pozzati, Liliana Antón, Rosario Barenys de Lacha, Mercé Angueira, Teresa Fernández Bermejo, Miguel Campillo, Ana Alcedo, Javier Pajares Villarroya, Ramón Mego, Marianela Bermejo, Fernando Domínguez Jiménez, José Titó, Llúcia Fernández, Nuria Pabón Carrasco, Manuel Cosme, Ángel Mata Romero, Pilar Alcaide, Noelia Ariño, Inés Maira, Tommaso Di Garre, Ana Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier |
| author |
Caldas, María |
| author_facet |
Caldas, María Pérez Aisa, Ángeles Castro Fernández, Manuel Bujanda, Luis Lucendo, Alfredo Rodrigo, Luis Huguet, José María Pérez Lasala, Jorge Molina Infante, Javier Barrio, Jesús Fernández Salazar, Luis Lanas, Ángel Perona, Mónica Domínguez Cajal, Manuel Ortuño, Juan Gómez Rodríguez, Blas Almela, Pedro Botargués, Josep María Núñez, Óscar Modolell, Inés Gómez, Judith Ruiz Zorrilla, Rafael Coba, Cristóbal De La Huerta, Alain Iyo, Eduardo Pozzati, Liliana Antón, Rosario Barenys de Lacha, Mercé Angueira, Teresa Fernández Bermejo, Miguel Campillo, Ana Alcedo, Javier Pajares Villarroya, Ramón Mego, Marianela Bermejo, Fernando Domínguez Jiménez, José Titó, Llúcia Fernández, Nuria Pabón Carrasco, Manuel Cosme, Ángel Mata Romero, Pilar Alcaide, Noelia Ariño, Inés Maira, Tommaso Di Garre, Ana Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier |
| author_role |
author |
| author2 |
Pérez Aisa, Ángeles Castro Fernández, Manuel Bujanda, Luis Lucendo, Alfredo Rodrigo, Luis Huguet, José María Pérez Lasala, Jorge Molina Infante, Javier Barrio, Jesús Fernández Salazar, Luis Lanas, Ángel Perona, Mónica Domínguez Cajal, Manuel Ortuño, Juan Gómez Rodríguez, Blas Almela, Pedro Botargués, Josep María Núñez, Óscar Modolell, Inés Gómez, Judith Ruiz Zorrilla, Rafael Coba, Cristóbal De La Huerta, Alain Iyo, Eduardo Pozzati, Liliana Antón, Rosario Barenys de Lacha, Mercé Angueira, Teresa Fernández Bermejo, Miguel Campillo, Ana Alcedo, Javier Pajares Villarroya, Ramón Mego, Marianela Bermejo, Fernando Domínguez Jiménez, José Titó, Llúcia Fernández, Nuria Pabón Carrasco, Manuel Cosme, Ángel Mata Romero, Pilar Alcaide, Noelia Ariño, Inés Maira, Tommaso Di Garre, Ana Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Infeccions per Helicobacter pylori Terapèutica Helicobacter pylori infections Therapeutics |
| topic |
Infeccions per Helicobacter pylori Terapèutica Helicobacter pylori infections Therapeutics |
| description |
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain. |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/174282 |
| url |
https://hdl.handle.net/2445/174282 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.3390/antibiotics10010013 Antibiotics, 2020, vol. 10, num. 1 https://doi.org/10.3390/antibiotics10010013 |
| dc.rights.none.fl_str_mv |
cc by (c) Caldas et al., 2020 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
cc by (c) Caldas et al., 2020 http://creativecommons.org/licenses/by/3.0/es/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) reponame:Dipòsit Digital de la UB instname:Universidad de Barcelona |
| instname_str |
Universidad de Barcelona |
| reponame_str |
Dipòsit Digital de la UB |
| collection |
Dipòsit Digital de la UB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869404102697418752 |
| score |
15.228081 |